X

Trial Profile

A Phase 2b trial for EVX-02 in combination with EVX-03 in adjuvant melanoma

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 10 Mar 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EVX-02 (Primary) ; EVX-03 (Primary)
Indications Malignant melanoma
Focus Therapeutic Use
Sponsors Evaxion Biotech

Most Recent Events

07 Mar 2022 According to an Evaxion media release, first patient first visit is expected in H2 2022 and an interim readout in 2023.
20 Nov 2021 New trial record
09 Nov 2021 According to an Evaxion media release, the company intends to submit a regulatory filing for a Phase 2b clinical trial of EVX-02 and EVX-03, in combination with anti-PD-1 in adjuvant melanoma in a three-arm trial, in the first half of 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com